| NAD+ metabolism governs the proinflammatory senescence-associated secretome T Nacarelli, L Lau, T Fukumoto, J Zundell, N Fatkhutdinov, S Wu, KM Aird, ... Nature cell biology 21 (3), 397-407, 2019 | 309 | 2019 |
| BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer S Karakashev, H Zhu, Y Yokoyama, B Zhao, N Fatkhutdinov, ... Cell reports 21 (12), 3398-3405, 2017 | 175 | 2017 |
| HMGB2 orchestrates the chromatin landscape of senescence-associated secretory phenotype gene loci KM Aird, O Iwasaki, AV Kossenkov, H Tanizawa, N Fatkhutdinov, BG Bitler, ... Journal of Cell Biology 215 (3), 325-334, 2016 | 162 | 2016 |
| N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance T Fukumoto, H Zhu, T Nacarelli, S Karakashev, N Fatkhutdinov, S Wu, ... Cancer research 79 (11), 2812-2820, 2019 | 148 | 2019 |
| NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer T Nacarelli, T Fukumoto, JA Zundell, N Fatkhutdinov, S Jean, ... Cancer research 80 (4), 890-900, 2020 | 119 | 2020 |
| EZH2 inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP inhibition S Karakashev, T Fukumoto, B Zhao, J Lin, S Wu, N Fatkhutdinov, PH Park, ... Cancer Cell 37 (2), 157-167. e6, 2020 | 104 | 2020 |
| Repurposing Pan-HDAC inhibitors for ARID1A-mutated ovarian cancer T Fukumoto, PH Park, S Wu, N Fatkhutdinov, S Karakashev, T Nacarelli, ... Cell reports 22 (13), 3393-3400, 2018 | 96 | 2018 |
| HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer T Fukumoto, N Fatkhutdinov, JA Zundell, EN Tcyganov, T Nacarelli, ... Cancer research 79 (21), 5482-5489, 2019 | 89 | 2019 |
| Potential therapeutic targets in ARID1A-mutated cancers BG Bitler, N Fatkhutdinov, R Zhang Expert opinion on therapeutic targets 19 (11), 1419-1422, 2015 | 71 | 2015 |
| Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma S Wu, T Fukumoto, J Lin, T Nacarelli, Y Wang, D Ong, H Liu, ... Nature cancer 2 (2), 189-200, 2021 | 63 | 2021 |
| Topoisomerase 1 cleavage complex enables pattern recognition and inflammation during senescence B Zhao, P Liu, T Fukumoto, T Nacarelli, N Fatkhutdinov, S Wu, J Lin, ... Nature communications 11 (1), 908, 2020 | 56 | 2020 |
| ARID1A promotes genomic stability through protecting telomere cohesion B Zhao, J Lin, L Rong, S Wu, Z Deng, N Fatkhutdinov, J Zundell, ... Nature communications 10 (1), 4067, 2019 | 52 | 2019 |
| SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells S Wu, N Fatkhutdinov, T Fukumoto, BG Bitler, PH Park, AV Kossenkov, ... Nature communications 9 (1), 4116, 2018 | 48 | 2018 |
| ARID1A spatially partitions interphase chromosomes S Wu, N Fatkhutdinov, L Rosin, JM Luppino, O Iwasaki, H Tanizawa, ... Science advances 5 (5), eaaw5294, 2019 | 39 | 2019 |
| Targeting RRM2 and mutant BRAF is a novel combinatorial strategy for melanoma N Fatkhutdinov, K Sproesser, C Krepler, Q Liu, PA Brafford, M Herlyn, ... Molecular Cancer Research 14 (9), 767-775, 2016 | 32 | 2016 |
| ARID2 deficiency correlates with the response to immune checkpoint blockade in melanoma T Fukumoto, J Lin, N Fatkhutdinov, P Liu, R Somasundaram, M Herlyn, ... Journal of Investigative Dermatology 141 (6), 1564-1572. e4, 2021 | 28 | 2021 |
| Harnessing mutual exclusivity between TP53 and ARID1 A mutations S Wu, N Fatkhutdinov, R Zhang Cell Cycle 16 (24), 2313-2314, 2017 | 9 | 2017 |
| The N6-methylation of adenosine (M6a) in Fzd10 mRNA contributes to resistance to parp Inhibitor T Fukumoto, H Zhu, S Karakashev, T Nacarelli, N Fatkhutdinov, S Wu, ... Clinical Cancer Research 25 (22), 204-204, 2019 | 3 | 2019 |
| T cell correction pipeline for Inborn Errors of Immunity K Mamia, S Kolbeinsdottir, Z Li, K Labun, A Komisarczuk, S Keskitalo, ... bioRxiv, 2024.09. 03.610811, 2024 | | 2024 |
| CRISPR-Cas9 T Cell Editing for Finnish Founder Diseases K Mamia, Z Li, G Reint, N Fatkhutdinov, F Haugen, T Gjerdingen, ... MOLECULAR THERAPY 30 (4), 455-455, 2022 | | 2022 |
